Irritable Bowel Syndrome Treatment Market – Global Industry Insights, and Opportunity Analysis 2025

Irritable bowel syndrome (IBS) causes bouts of stomach cramps, diarrhea, bloating or constipation, where it is a common and long-term condition of the digestive systems. The symptoms of this syndrome vary according to individuals and can last from few days to a few months at a time. It is also observed during stress or after eating certain food. It is a gastrointestinal disorder of the gut that is characterized by colon muscle contractions that mainly affects the large intestine. It is mainly observed in elderly people.

Request a sample copy of this report: http://bit.ly/2fsun46

By Disease Type

  • IBS With Constipation
  • IBS With Diarrhea
  • IBS With Alternating Constipation and Diarrhea

By End User

  • Hospital
  • Clinics
  • Homecare Settings

Rise in novel therapeutic classes fuels growth of the irritable bowel syndrome treatment market

As of 2016, there are only 2 medications approved by Food Drug Administration (FDA) for irritable bowel syndrome, namely Alosetron (Lotronex) and Lubiprostone (Amitiza) and both these medications are proved right only in women in the U.S. LINZESS is FDA approved to treat IBS with constipation in both men and women, while in Japan, Irribow drug (ramosetron) is available. Due lack of drugs with safety and efficacy there is weak competition between manufacturers. However, the market scenario is expected to change after the launch of new disease treatment medications. Rifaximin (Xifaxan) is an antibiotic approved in May 2015 by FDA in the U.S. for treatment of IBS with diarrhea in adults. According to International Foundation for Functional Gastrointestinal Disorders, Inc. (IFFGD) new prescription drugs are being studied currently but have not yet approved by FDA for treatment. Drugs for IBS with constipation are currently in third phase of clinical trials that include plecanatide, and elobixibat which is a first-in-class compound. These new drugs are expected to show rise in irritable bowel syndrome treatment market in the near future.

Ask for customization: http://bit.ly/2yBuxL1

Asia Pacific to be Growth Engine of the Irritable Bowel Syndrome Treatment Market

Irritable bowel syndrome treatment is segmented geographically into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. New drugs with improved efficacy which provide relief to irritable bowel syndrome and increase in awareness regarding chronic nature of the syndrome favors the growth of irritable bowel syndrome treatment market in Asia-Pacific. Most of the drugs are approved only for the U.S., making it the key geographic region for irritable bowel market. Europe also favors the market due to rising incidence of irritable bowel syndrome in the region.

Key players operating in irritable bowel syndrome treatment market

Key players in irritable bowel syndrome treatment market include Sucampo Pharmaceuticals, Inc., Ironwood Pharmaceuticals, valeant Pharmaceuticals International Inc., Lexicon Pharmaceuticals, Abbott Laboratories, Salix Pharmaceuticals, Inc., Allergan Plc and GlaxoSmithKline plc.

Click here to know more about this report: https://www.coherentmarketinsights.com/ongoing-insight/irritable-bowel-syndrome-treatment-market-506

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: